Difference between revisions of "Team:Nagahama/Intgrated Human Practice"
| Line 378: | Line 378: | ||
<li class="menu_item"> <div class="icon plus"></div> PROJECT | <li class="menu_item"> <div class="icon plus"></div> PROJECT | ||
<ul class="submenu"> | <ul class="submenu"> | ||
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Introduction"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Introduction"> ・Introduction </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Result and Discussion"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Result and Discussion"> ・Result and Discussion </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Future"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Future"> ・Future </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Protocol"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Protocol"> ・Protocol </a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| Line 387: | Line 387: | ||
<li class="menu_item"> <div class="icon plus"></div> BioBricks | <li class="menu_item"> <div class="icon plus"></div> BioBricks | ||
<ul class="submenu"> | <ul class="submenu"> | ||
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Our all BioBricks"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Our all BioBricks"> ・Our all BioBricks </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/BioBricks for medal"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/BioBricks for medal"> ・BioBricks for medal </a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| Line 397: | Line 397: | ||
<li class="menu_item"> <div class="icon plus"></div> Attributions | <li class="menu_item"> <div class="icon plus"></div> Attributions | ||
<ul class="submenu"> | <ul class="submenu"> | ||
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Team"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Team"> ・Team</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Attributions"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Attributions"> ・Attributions </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Sponsors"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Sponsors"> ・Sponsors</a></li> |
</ul> | </ul> | ||
| Line 407: | Line 407: | ||
<li class="menu_item"> <div class="icon plus"></div> Collaborations | <li class="menu_item"> <div class="icon plus"></div> Collaborations | ||
<ul class="submenu"> | <ul class="submenu"> | ||
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Collaborations"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Collaborations"> ・Collaborations</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/The Annual Meeting Of The Genetics Society Of Japan"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/The Annual Meeting Of The Genetics Society Of Japan"> ・The Annual Meeting Of The Genetics Society Of Japan </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Support Gifu"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Support Gifu"> ・Support Gifu</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/virginia"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/virginia"> ・Virginia</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Paris-Saclay"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Paris-Saclay"> ・Paris-Saclay</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Munich United"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Munich United"> ・Munich United</a></li> |
| Line 422: | Line 422: | ||
<li class="menu_item"> <div class="icon plus"></div> Human Practice | <li class="menu_item"> <div class="icon plus"></div> Human Practice | ||
<ul class="submenu"> | <ul class="submenu"> | ||
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Human Practice"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Human Practice"> ・Human Practice </a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Contacting Local"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Contacting Local"> ・Contacting Local</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Contacting Japan"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Contacting Japan"> ・Contacting Japan</a></li> |
| − | <li> <a href="https://2016.igem.org/Team:Nagahama/Intgrated Human Practice"> | + | <li> <a href="https://2016.igem.org/Team:Nagahama/Intgrated Human Practice"> ・Intgrated Human Practice</a></li> |
Latest revision as of 16:20, 19 October 2016
We explained our project and synthetic biology to the local people.Furthermore, in order to make our project and synthetic biology known nationwide, we used website, television programs, newspapers and radio.As a result, we received some useful feedbacks from the general public.Two of the feedbacks raised very important issued. First issue "Fragrance on food"When food is kept an ‘Flavorator’, the fragrance might adhere to the food that you want to preserve.Second issue "Recombinant, may go out of the laboratory. ⇒Recombinant releases"Each solution of these problems to be integrated with the project.
About the first issue
We decided to use farnesol from the scent ingredient, with antibacterial properties, because it is almost odorless.This was the target, and solve the first Issue.
About the second issue
A method in which antimicrobial volatile gaseous substances synthesized using only the endogenous gene of E. coli.Specifically, we used the CRISPR-Cas9.Gene of extra in pathway to synthesis of farnesol, unnecessary intermediate metabolite (non-essential) synthase gene, knocked out.Gene involved in farnesol synthesized by those of endogenous E. coli knock in.Two issues are solved by these solutions.Integrated was completed.
